Skip to main content
Clinical Trials/NCT04685096
NCT04685096
Completed
Not Applicable

Efficacy Evaluation of the Anti-ageing Effect of a Cosmetic Active Versus Placebo

Seneque SA2 sites in 2 countries89 target enrollmentDecember 12, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Wrinkle
Sponsor
Seneque SA
Enrollment
89
Locations
2
Primary Endpoint
Wrinkles
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

The study aims at evaluating skin wrinkling, puffiness and fatigue and dark circle appearance on asian and african-american healthy volunteer cohorts receiving a cosmetic formulation containing NMN (2%). The product will be evaluated after 28 and 56 days of twice-daily application in comparison with a reference cosmetic formulation using clinical scoring under dermatological control. Cosmetic acceptability and future use will also be subjectively evaluated by analysis of the subjects answers to an evaluation questionnaire.

Registry
clinicaltrials.gov
Start Date
December 12, 2020
End Date
April 16, 2021
Last Updated
5 years ago
Study Type
Observational
Sex
Female

Investigators

Sponsor
Seneque SA
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Healthy subject
  • Subject having given her free informed, written consent
  • Subject willing to adhere to the protocol and study procedures
  • Subject with normal frontal temperature lower than 37.5°c/100.4°F
  • Subject has read and understood the information given by the investigator related to protection against Novel Coronavirus 19 and necessity to contact the investigator in case of any suspicion of COVID related manifestation (increase of frontal temperature, cough, sore muscles, weakness...) during the study

Exclusion Criteria

  • Pregnant or nursing woman or woman planning to get pregnant during the study
  • Start, stop or change in hormonal treatment (including contraceptive pill) \<1.5 months
  • Cutaneous pathology on the study zone (face)
  • Use of topical or systemic treatment during the previous weeks liable to interfere with the assessment of the cutaneous efficacy of the study product
  • Subject having undergone a surgery under general anesthesia within the previous month
  • Know allergy to certain cosmetic or dermato-pharmaceutic products
  • Subject having done injections on face and/or a lifting
  • Excessive exposure to sunlight or UV-rays within the month preceding the study

Outcomes

Primary Outcomes

Wrinkles

Time Frame: Change from baseline (day 0) at days 28 and 56 of application

clinical grading under dermatological control using 1) a 7 points Visual scale of Bazin from absence (0) to pronounced wrinkles (6) for the Asian panel and 2) a 5 points Visual scale of Bazin from absence (0) to pronounced wrinkles (4) for the Afro-American panel

Relaxed features

Time Frame: Change from baseline (day 0) at days 28 and 56 of application

clinical grading under dermatological control using a 11 points Non structured scale from relaxed features (0) to looking tired (10) for both panels

Eye bags

Time Frame: Change from baseline (day 0) at days 28 and 56 of application

clinical grading under dermatological control using 1) a 7 points Visual scale of Bazin from absence (0) to pronounced bags (6) for the Asian panel and 2) a 6 points Visual scale of Bazin from absence (0) to pronounced bags (5) for the Afro-American panel

Dark circles

Time Frame: Change from baseline (day 0) at days 28 and 56 of application

clinical grading under dermatological control using 1) a 6 points Visual scale of Dermscan from absence (0) to important dark circles (6) for the Asian panel and 2) a 5 points Visual scale of Dermscan from absence (0) to important dark circles (4) for the Afro-American panel

Secondary Outcomes

  • Subjective evaluation of the product agreeableness and its effects on skin texture, moisture, puffiness, brightness, youth, swelling, wrinkling, radiance and tone.(At day 56 of application)

Study Sites (2)

Loading locations...

Similar Trials